AKT1 and Behcet disease: In this current study, we used the olfactory neuroepithelium platform to conduct transcriptional profiling of AKT1, PKCε, and GSK3β in BD patients at baseline (i.e., before initiation of lithium therapy) and after a 6-week course of lithium therapy.